Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States.

Jyoti Malhotra¹, Elizabeth H Marchlewicz², Yan Zhang³, Isabelle Winer², Kenneth Pack², Christopher Danes³, Hoa H Le⁴, Luis Hernandez⁵

¹City of Hope, Duarte, CA, USA.

²Veradigm, Chicago, IL, USA.

³Takeda Pharmaceuticals America, Inc., Lexington, MA, USA.

⁴Takeda Development Center America, Inc., Cambridge, MA, USA.

⁵Takeda Pharmaceuticals America, Inc., Lexington, MA, USA. luis.hernandez3@takeda.com.

PubMed DOI

Abstract

INTRODUCTION: This study evaluated the real-world utilization, effectiveness, occurrence of adverse events (AEs), and healthcare costs in patients treated with next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), alectinib, brigatinib, and lorlatinib, among ALK TKI-naïve patients with ALK rearrangement-positive metastatic non-small cell lung cancer (ALK + mNSCLC) in t…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.